Researchers at the University of Cambridge have developed a groundbreaking vaccine using artificial intelligence, marking what scientists describe as a major step toward preventing future pandemics.
The experimental vaccine is the first to have its key component designed entirely by artificial intelligence before being tested in human volunteers.
Scientists say the technology could transform vaccine development by creating broad protection against entire families of viruses rather than targeting a single strain.
The first vaccine developed using the approach focuses on coronaviruses, the family of viruses responsible for COVID-19, SARS and MERS.
Researchers believe the vaccine could potentially provide protection against current coronavirus variants, future mutations and even animal-borne coronaviruses that could trigger future pandemics.
The development represents a significant shift from traditional vaccine design methods, which are typically based on existing virus strains.
According to Professor Jonathan Heeney of the University of Cambridge, the goal is to stay ahead of emerging viral threats rather than continually reacting to outbreaks after they occur.
“We’re always behind,” Heeney said.
“What we’re trying to do is get ahead of the curve.”
He explained that the long-term objective is to create vaccines capable of protecting against viruses that have not yet emerged in humans.
“This is about making vaccines that protect us, not just from today’s viruses, but protect us from what can cause the next outbreak or disease,” he said.
“This is a fundamental shift in how we prepare for pandemics.”
To create the vaccine, researchers collected genetic data from multiple coronaviruses identified through global surveillance programmes designed to detect potential viral threats.
Artificial intelligence then analysed the genetic information and designed what scientists describe as a “super-antigen.”
Antigens are the critical elements of vaccines that train the immune system to recognise and attack viruses.
Rather than targeting a specific coronavirus, the AI-designed antigen was engineered to teach the immune system how to recognise common features shared across the entire virus family.
Scientists believe this approach could maintain effectiveness even if viruses mutate or if new infections emerge from animals and spread to humans.
The vaccine has already undergone an initial human safety trial involving 39 participants.
Researchers reported that the trial demonstrated the vaccine was safe, while early immune responses were described as modest but encouraging.
A larger follow-up study involving approximately 200 participants is now underway to evaluate how effectively the vaccine stimulates the immune system.
The findings were published in the Journal of Infection and have attracted significant interest from scientists working on pandemic preparedness.
Professor Saul Faust of the University of Southampton, who participated in some of the clinical trials, described the technology as highly promising.
“This definitely has potential,” he said.
“What’s really interesting is the technology is an awful lot better at designing vaccines for potential pandemics when viruses are changing.”
The Cambridge team is already expanding the technology beyond coronaviruses.
Researchers are conducting animal studies on a universal seasonal influenza vaccine that could eliminate the need for annual updates.
They are also developing an H5N1 bird flu vaccine to prepare for the possibility of a future influenza pandemic.
In addition, scientists are investigating vaccines for viral haemorrhagic fevers, including Ebola.
The research comes as health authorities continue to monitor Ebola outbreaks in parts of Africa, including the Democratic Republic of Congo, where some virus strains still lack approved vaccines.
Experts say artificial intelligence could significantly accelerate vaccine development by identifying effective vaccine targets much faster than conventional methods.
Professor Andy Pollard, Director of the Oxford Vaccine Group, said the findings represent an important scientific breakthrough.
“It’s fascinating data and people wouldn’t have predicted they’d be able to generate these immune responses,” he said.
However, he noted that larger human trials will be necessary to determine whether the approach delivers the same level of success observed in laboratory studies.
Pollard also described artificial intelligence as a potential “game changer” for vaccine research.
According to him, AI could help scientists predict immune responses more accurately, reduce development timelines and improve preparedness for future disease outbreaks.
Professor Marian Knight, Scientific Director at the National Institute for Health and Care Research, also welcomed the results.
“The remarkable success of this AI-designed ‘super-antigen’ trial marks a pivotal leap forward in our ability to deliver broad, lasting viral protection,” she said.
While further testing is required before the technology can be widely deployed, researchers believe AI-designed vaccines could eventually become a powerful tool in preventing pandemics and strengthening global health security.
